Mode
Text Size
Log in / Sign up
N/A Completed N=19 Treatment

Multicenter Dispensing Study of Biofinity Lenses in Extended Range

Source: ClinicalTrials.gov NCT02060539 ↗
Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Jun 2015
Primary outcomePrimary: Dryness (During Day and Dryness at Night) — 69; 53 units on a scale

Summary

To obtain subjective and objective feedback on the clinical performance of Biofinity lenses after at least two weeks daily wear in existing contact lens wearers compared with their habitual lenses.

Outcome Measures

OutcomeResultp-value
PRIMARY
Dryness (During Day and Dryness at Night)
87; 76
PRIMARY
Dryness (During Day)
92
PRIMARY
Dryness (During Day and Dryness at Night)
87; 76
PRIMARY
Comfort (Insertion, End of Day, Overall)
89; 76; 86
PRIMARY
Comfort (Insertion)
89
PRIMARY
Comfort (Insertion, End of Day, Overall)
89; 76; 86
PRIMARY
Ghosting (Multiple Images)
92
PRIMARY
Ghosting (Multiple Images)
92
PRIMARY
Ghosting (Multiple Images)
92
PRIMARY
Hazing (Blurred Edges)
92
PRIMARY
Hazing (Blurred Edges)
92
PRIMARY
Vision Quality (During Day and at Night)
86; 78
PRIMARY
Vision Quality (During Day)
87
PRIMARY
Vision Quality (During Day and at Night)
86; 78
PRIMARY
Handling (Insertion, Removal, Overall)
94; 83; 89
PRIMARY
Handling (Insertion, Removal, Overall)
94; 83; 89
PRIMARY
Overall Satisfaction of Comfort, Vision, Handling
87
PRIMARY
Overall Satisfaction of Comfort, Vision, Handling
87
PRIMARY
Overall Satisfaction of Comfort, Vision, Handling
87
PRIMARY
Comfort Preference
42; 26; 32
PRIMARY
Comfort Preference
42; 26; 32
PRIMARY
Vision Preference
53; 31; 16
PRIMARY
Vision Preference
53; 31; 16
PRIMARY
Handling Preference
32; 32; 37
PRIMARY
Overall Preference
63; 21; 16
PRIMARY
Overall Preference
63; 21; 16
SECONDARY
Lens Centration - Habitual Lenses
53; 37; 11
SECONDARY
Lens Centration
63; 32; 5
SECONDARY
Lens Centration
63; 32; 5
SECONDARY
Lens Movement - Habitual Lenses
2.47
SECONDARY
Lens Movement
2.45
SECONDARY
Lens Movement
2.45
SECONDARY
Overall Fit Acceptance
3.45
SECONDARY
Overall Fit Acceptance
3.45
SECONDARY
Overall Fit Acceptance
3.45
SECONDARY
Visual Acuity
0.11; 0.18; 0.02; 0.11
SECONDARY
Visual Acuity
0.11; 0.18; 0.02; 0.11
SECONDARY
Visual Acuity
0.11; 0.18; 0.02; 0.11
SECONDARY
Anterior Ocular Physiological Response
1.00; 0.74; 0.47; 0.45; 0.94; 0.9
SECONDARY
Anterior Ocular Physiological Response
1.00; 0.74; 0.47; 0.45; 0.94; 0.9
SECONDARY
Average Wearing Time
12.5
SECONDARY
Average Wearing Time
12.5

Eligibility Criteria

Inclusion Criteria

  • Has had an oculo-visual examination in the last two years
  • Is at least 18 years of age and has full legal capacity to volunteer
  • Has read and understood the information consent letter
  • Is willing and able to follow instructions and maintain the appointment schedule
  • Is correctable to a visual acuity of 20/50 or better (in at least one eye) with their habitual vision correction
  • Currently wears soft contact lenses
  • They should require contact lens powers between -12.00 and -20.00D or between +8.00 and +15.00D
  • Has clear corneas and no active ocular disease
  • Demonstrates an acceptable fit with the study lenses.

Exclusion Criteria

  • Has any systemic disease affecting ocular health
  • Is taking medication, such as antihistamine eye drops, oral and ophthalmic betaadrenergic blockers (e.g. Propanolol, Timolol), anticholinergics, and any prescribed or over-the-counter eye medication, except artificial tears or eye lubricants
  • Have any active ocular disease and/or infection that would contraindicate contact lens wear.
  • Active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
  • Has worn gas permeable contact lenses within the last month.
  • Is aphakic
  • Has undergone corneal refractive surgery.
  • Is participating in any other type of clinical research study
  • Female who is currently pregnant or is breast-feeding.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02060539). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search